Research Study

An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures
Principal Investigator 
Jerry C.L. Chen

Overview

Body Locations and Systems 
Peripheral Arterial Disease
ClinicalTrials.gov# 
NCT02504216
Status 
Recruiting
Study Start/End 
Sep 28, 2016 to May 2, 2019
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Lynn Cunada, Research Coordinator
Phone 
604-875-5077
Purpose of Study 

The purpose of study is to test whether rivaroxaban added to standard of care treatment, when compared to placebo, has the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs. 

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.